Significance of keratinocyte growth factor receptor in the proliferation of biliary tract cancer

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4115-4121

  Amano, Ryosuke ^a   Yamada, Nobuya ^a   Doi, Yosuke ^a   Yashiro, Masakazu ^a   Ohira, Masaichi ^a   Miwa, Atsushi ^b   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Biliary tract cancer; KGFR; Phosphorylation inhibitor

Indexed keywords

KERATINOCYTE GROWTH FACTOR RECEPTOR; KI 23057; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BILE DUCT CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GALLBLADDER CANCER; HEPATOBILIARY SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ANIMALS; APOPTOSIS; BILIARY TRACT NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; QUINOLINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RNA, MESSENGER; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS;

EID: 78650231488     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Tonini G, Virzi V, Fratto ME, Vincenzi B and Santini D: Targeted therapy in biliary tract cancer: 2009 update. Future Oncol 5: 1675-1684, 2009.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T: Cancer incidence and incidence rates in Japan in 2002: Based on data from 11 population-based cancer registries. Jpn J Clin Oncol 38: 641-648, 2008.
3. Seyama Y and Makuuchi M: Current surgical treatment for bile duct cancer. World J Gastroenterol 13: 1505-1515, 2007.
4. Ustundag Y and Bayraktar Y: Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol 14: 6458-6466, 2008.
5. Wise C, Pilanthananond M, Perry BF, Alpini G, McNeal M and Glaser SS: Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol 14: 2986-2989, 2008.
6. Fava G, Marzioni M, Benedetti A, Glaser S, DeMorrow S, Francis H and Alpini G: Molecular pathology of biliary tract cancers. Cancer Lett 250: 155-167, 2007.
7. Thomas MB: Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol 61: 44-51, 2007.
8. Hezel AF and Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 13: 415-423, 2008.
9. Verslype C, Prenen H and Van Cutsem E: The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 10: 164-167, 2008.
10. Nakazawa K, Yashiro M and Hirakawa K: Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer research 63: 8848-8852, 2003.
11. Nakanuma Y, Harada K, Ishikawa A, Zen Y and Sasaki M: Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 10: 265-281, 2003.
12. Sobin LH: TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 21: 19-22, 2003.
13. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T and Terada M: Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2: 1373-1381, 1996.
14. Yamada N, Chung YS, Arimoto Y, Sawada T, Seki S and Sowa M: Establishment of a new human extrahepatic bile duct carcinoma cell line (OCUCh-LM1) and experimental liver metastatic model. Br J Cancer 71: 543-548, 1995.
15. Yamada N, Chung YS, Ohtani H, Ikeda T, Onoda N, Sawada T, Nishiguchi Y, Hasuma T and Sowa M: Establishment and characterization of a new human gallbladder carcinoma cell line (OCUG-1) producing TA-4. Int J Oncol 10: 1251-1255, 1997.
16. Sun J, Qian Y, Hamilton AD and Sebti SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55: 4243-4247, 1995.
17. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A and Hirakawa K: A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology 131: 1530-1541, 2006.
18. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M and Ornitz DM: Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281: 15694-15700, 2006.
19. Ueda T, Sasaki H, Kuwahara Y, Nezu M, Shibuya T, Sakamoto H, Ishii H, Yanagihara K, Mafune K, Makuuchi M and Terada M: Deletion of the carboxyl-terminal exons of K-SAMIFGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res 59: 6080-6086, 1999.
20. Katoh M: FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. Int J Oncol 22: 1155-1159, 2003.
21. Sirica AE, Lai GH and Zhang Z: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 16: 363-372, 2001.
22. Ogasawara S, Yano H, Higaki K, Takayama A, Akiba J, Shiota K and Kojiro M: Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol Res 20: 97-113, 2001.
23. Kubicka S, Rudolph KL, Tietze MK, Lorenz M and Manns M: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48: 783-789, 2001.
24. Thongprasert S, Napapan S, Charoentum C and Moonprakan S: Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16: 279-281, 2005.
25. Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H and Kim YH: Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 35: 68-73, 2005.
26. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P and Fuchs CS: Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 53: 564-570, 2008.
27. Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E and Colucci G: Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol 17(Suppl 7): vii73-77, 2006.
28. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F and Scheithauer W: Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56: 177-180, 1999.
29. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS and Stuart KE: A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82: 2321-2325, 1998.
30. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V and Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27: 1999-2006, 2009.
31. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F and Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.